The decisions that determine Phase 2 timing are made, or missed, in the first two quarters after the IND opens.
White Paper
IND Ready Is Not Phase 2 Ready
Related Resources
All Resources
post
Manufacturing Gaps in the U.S. Pharmaceutical Industry Exposed by Tariff Wars
Read More
white-paper
Assessing Animal-Derived Raw Materials for Viral Risk
Read More
post
What is Fast-Track Designation? Accelerating Life-Saving Drug Development
Read More
post
The Strategic Role of Regulatory Affairs in the Pharmaceutical Industry
Read More
Let's move from science to success.
Let’s Talk